Bolesław23 pokaż swoje. Pośmiejemy się. Sog dla Ciebie.
According to convention if we inject oil-based anabolic androgenic steroids into the fat layer beneath the skin and above the muscle (subcutaneous) it will impair absorption and could delay dissapation of drugs for many weeks or months. New research conducted at the Royal Victoria Hospital in Canada at the endocrine clinic tested the viability of subcutaneous shots.
The study involved 22 patients who were using the clinic for testosterone replacement therapy. The anabolic androgenic steroids was
testosterone enanthate. The subjects were instructed to self-administer their testosterone subcutaneously once per week. The same 1ml that would have been injected once every 2 weeks was divided up into .5ml weekly injections. Blood tests which were conducted periodically throughout the 1 year investigation were suprisingly and unquestionably consistent. For exactly 100% of patients enrolled, testosterone levels remained in the physiological (normal) range for the entire duration of the study. This included both peak and trough levels (high & low during each week). Furthermore injections were extremely well tolerated. Each patient took over 50 injections and not one single adverse reactionn was noticed at the injection site.
The investigation concluded that not only was subcutaneous testosterone enanthate a viable option as far as drug release , but it was safe, cheap and far more comfortable for their patients compared to intramuscular injections.
Al-Futaisi AM, Al-Zakwani IS, Almahrezi AM, Morris D. Subcutaneous administration of testosterone. A pilot study report. Saudi Med J. 2006;27(12):1843-6.
ABSTRACT
OBJECTIVE: To investigate the effect of low doses of subcutaneous testosterone in hypogonadal men since the intramuscular route, which is the most widely used form of testosterone replacement therapy, is inconvenient to many patients. METHODS: All men with primary and secondary hypogonadism attending the reproductive endocrine clinic at Royal Victoria Hospital, Monteral, Quebec, Canada, were invited to participate in the study. Subjects were enrolled from January 2002 till December 2002. Patients were asked to self-administer weekly low doses of testosterone enanthate using 0.5 ml insulin syringe. RESULTS: A total of 22 patients were enrolled in the study. The mean trough was 14.48 +/- 3.14 nmol/L and peak total testosterone was 21.65 +/- 7.32 nmol/L. For the free testosterone the average trough was 59.94 +/- 20.60 pmol/L and the peak was 85.17 +/- 32.88 pmol/L. All of the patients delivered testosterone with ease and no local reactions were reported. CONCLUSION: Therapy with weekly subcutaneous testosterone produced serum levels that were within the normal range in 100% of patients for both peak and trough levels. This is the first report, which demonstrated the efficacy of delivering weekly testosterone using this cheap, safe, and less painful subcutaneous route.
BBolek
Krzysztof Piekarz
tekaen
lodzianin1
wnc1964
Naly
jak nikt nie bił to zawsze ktos musi sprobowac by przetrzec nowe szlaki i doswiadczyc czegos nowego 
red face
